Zydus gains FDA Priority Review for saroglitazar as PBC treatment competition intensifies
Zydus’ saroglitazar gets FDA Priority Review in PBC, setting up a key test for dual PPAR therapy in rare liver disease.
Why Assembly Biosciences’ liver disease strategy now extends far beyond viral hepatitis
Assembly Biosciences is expanding ABI-6250 beyond HDV into PBC and PSC. Find out why NTCP inhibition is gaining industry attention.